Novartis Names Sandoz Board Chairman Ahead of Spinoff
20 Fevereiro 2023 - 3:58AM
Dow Jones News
By Joshua Kirby
Novartis AG said Monday that it is appointing Gilbert Ghostine
to chair the board of directors of its generics division Sandoz,
which the drug maker is in the process of spinning off.
Mr. Ghostine has been chief executive of Geneva-based perfume
maker Firmenich since 2014 and previously also held executive
positions at drinks group Diageo PLC, Novartis said. He will become
chairman of the Sandoz board following board and shareholder
approval, the Swiss company said.
Novartis last year set out a plan to strip away Sandoz and focus
on its core business, a process set to be completed in the second
half of this year.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
February 20, 2023 01:43 ET (06:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024